Table 2.
Univariate analysis of the significance of different prognostic variables in nasopharyngeal carcinoma
|
Factors |
DMFS |
OS |
||||
|---|---|---|---|---|---|---|
| Pvalue | HR | 95% CI | Pvalue | HR | 95% CI | |
|
Age (>50 yr vs. ≤50 yr) |
0.02 |
1.90 |
1.09–3.35 |
<0.01 |
2.15 |
1.22–3.81 |
|
Sex (female vs. male) |
0.82 |
0.93 |
1.48–1.78 |
0.66 |
0.86 |
0.44–1.69 |
|
Chemotherapy (yes vs. no) |
0.14 |
1.78 |
0.83–3.79 |
0.26 |
1.52 |
0.73–3.13 |
|
Radiotherapy (IMRT vs.2D-RT) |
0.99 |
1.00 |
0.80–1.25 |
0.93 |
1.01 |
0.81–1.26 |
|
T stage (T3–4 vs. T1–2) |
0.13 |
1.55 |
0.88–2.74 |
0.06 |
1.77 |
0.99–3.18 |
|
N stage (N2–3 vs. N0–1) |
0.02 |
1.98 |
1.13–3.47 |
0.01 |
2.06 |
1.17–3.63 |
|
Clinical stage (III-IV vs. I-II) |
0.01 |
2.52 |
1.22–5.19 |
<0.01 |
2.78 |
1.30–5.95 |
| MTA1 expression (high vs. low) | <0.01 | 2.25 | 1.25–4.05 | <0.01 | 2.19 | 1.21–3.97 |
Abbreviation: DMFS distant metastasis free-survival; OS overall survival; IMRT intensity-modulated radiotherapy; 2D-RT two-dimensional radiotherapy.